Skip to main content
. 2019 Apr 13;8(7):1599636. doi: 10.1080/2162402X.2019.1599636

Figure 2.

Figure 2.

Urelumab increases daratumumab-mediated NK cell activation. (a) Urelumab increases CD25 expression on NK cells cultured during 16h with IL-2 and immobilized IgG and then cocultured 24h/48h with MM1S-GFP-Luc cells, daratumumab, and urelumab. (b) Percentage of CD137+ NK cells among the CD25+ and CD25− cell fractions of the corresponding co-cultures of NK cells as in A. A representative FACS contour plot is shown. (c) Urelumab increases IFNɣ intracellular expression in NK cells cultured as in A. (d) Urelumab increases IFNɣ release to the supernatant by NK cells cultured as in A. This graph shows data of one experiment from three independently performed with similar results. (e) Percentage of CD137+ NK cells among the IFNɣ+ and IFNɣ− cell fractions of the corresponding co-cultures of NK cells as in A. A representative FACS contour plot is shown. Cytometry results are representative of five different donors. * = p < 0.05, ** = p < 0.01 and *** = p < 0.001 in a paired t-Test or one-way ANOVA test.